Vimarsana
Biggest News Aggregation in the World

Toxicology Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Toxicology Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Toxicology Study Today - Breaking & Trending Today

Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder - Vimarsana News

Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder

Published: January 4, 2024

Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). In November, Silo Pharma announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15. The study aims to identify the maximum tolerated intranasal dose of th

Source: yahoo.com
Related Topics:
Eric WeisblumSilo Pharma IncSilo PharmaMedspray PharmaChief Executive OfficerInvestigational New DrugStock Market GameBenzinga ProDay TrialSilo Pharma Concludes First PhasePharmacokinetic StudyDose Ranging StudyToxicology StudyTherapeutic Drug
Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update - Vimarsana News

Benitec Biopharma Inc.: Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

Published: February 13, 2023

HAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic

Source: finanznachrichten.de
Related Topics:
United StatesWilliam WindhamClinical Development Program OverviewBenitec Or CompanyBenitec Biopharma IncSolebury Strategic CommunicationsExchange CommissionRegulatory Updates For The Clinical Development ProgramResearch Ethics BoardAssay Method DevelopmentSecond Fiscal QuarterExecutive ChairmanChief Executive OfficerOculopharyngeal Muscular DystrophyDevelopment Program OverviewTreatment EvaluationPharyngeal ResidueMaximum ConstrictionImaging GradeSwallowing Toxicity ScalePyriform Sinus ResidueResidue Ratio ScaleConstruction RatioTreatment StudyClinical Development Program
Curative Biotechnology, Inc.?: Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study - Vimarsana News

Curative Biotechnology, Inc.?: Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study

Published: January 5, 2023

Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare

Source: finanznachrichten.de
Related Topics:
Paul MichaelsSteve ChizzikBoca RatonDevelopment AgreementSecurities ExchangeCurative Biotechnology IncInvestigational New DrugToxicology StudyTopical InstillationCurative BiotechnologyIntermediate Dry Age Related Macular DegenerationGeographical AtrophyCooperative ResearchNational Eye InstituteNational InstitutesBethesda MarylandMacular DegenerationGeographic AtrophyCurative BiotechAge Related Macular DegenerationSecurities ActSecurities Exchange Act
Theralase® Closes $2.5M Private Placement Equity Financing - Vimarsana News

Theralase® Closes $2.5M Private Placement Equity Financing

Published: September 22, 2022

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

Source: globenewswire.com
Related Topics:
United StatesKristina HacheyYork Stock ExchangeCompany Photo Dynamic CompoundsGood Laboratory PracticeToronto Stock ExchangeAmerican Stock ExchangeTechnologies IncNew York Stock ExchangeParty TransactionsCompany Common ShareVenture ExchangeRegulation Services ProviderPhoto Dynamic CompoundsEach WarrantCommon ShareCommon SharesLaboratory PracticeToxicology StudyNon Small Lung CancerGlio Blastoma MultiformeMuscle Invasive Bladder CancerUnited States Securities ActMultilateral InstrumentMinority Security Holders
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update - Vimarsana News

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Published: September 2, 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Related Topics:
United StatesBenitec BiopharmaWilliam WindhamCentral Ethics CommitteeClinical Development Program OverviewBenitec Biopharma IncSolebury Strategic CommunicationsExchange CommissionRegulatory Updates For The Clinical Development ProgramResearch Ethics BoardAssay Method DevelopmentFiscal YearExecutive ChairmanChief Executive OfficerOculopharyngeal Muscular DystrophyDevelopment Program OverviewPharyngeal ResidueMaximum ConstrictionImaging GradeSwallowing Toxicity ScalePyriform Sinus ResidueResidue Ratio ScaleConstruction RatioTreatment StudyRegulatory Updates